TY  - JOUR
AU  - Claeys, Carine
AU  - Drame, Mamadou
AU  - García-Sicilia, José
AU  - Zaman, Khalequ
AU  - Carmona, Alfonso
AU  - Tran, Phu My
AU  - Miranda, Mariano
AU  - Martinón-Torres, Federico
AU  - Thollot, Franck
AU  - Horn, Michael
AU  - Schwarz, Tino F
AU  - Behre, Ulrich
AU  - Merino, José M
AU  - Sadowska-Krawczenko, Iwona
AU  - Szymański, Henryk
AU  - Schu, Peter
AU  - Neumeier, Elisabeth
AU  - Li, Ping
AU  - Jain, Varsha K
AU  - Innis, Bruce L
PY  - 2018
DO  - 10.1186/s12879-018-3079-8
UR  - http://hdl.handle.net/10668/12365
T2  - BMC infectious diseases
AB  - GSK has modified the licensed monovalent bulk manufacturing process for its split-virion inactivated quadrivalent influenza vaccine (IIV4) to harmonize the process among different strains, resulting in an increased number of finished vaccine doses,...
LA  - en
KW  - Adults
KW  - Children
KW  - Immunogenicity
KW  - Infants
KW  - Influenza vaccine
KW  - Investigational
KW  - Manufacturing
KW  - Quadrivalent
KW  - Reactogenicity
KW  - Safety
KW  - Adolescent
KW  - Adult
KW  - Child
KW  - Child, Preschool
KW  - Cohort Studies
KW  - Double-Blind Method
KW  - Female
KW  - Fever
KW  - Hemagglutination Inhibition Tests
KW  - Humans
KW  - Infant
KW  - Influenza Vaccines
KW  - Influenza, Human
KW  - Male
KW  - Middle Aged
KW  - Vaccines, Inactivated
TI  - Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults.
TY  - research article
VL  - 18
ER  -